Title: Immune Checkpoint Inhibitor Therapy- Related Hypophysitis: A Case Report
Authors: Kreze A, Roulová J, Klemperová K, Papp P, Šíp O
DOI: https://dx.doi.org/10.18535/jmscr/v7i5.133
Abstract
Hypophysitis due to programmed cell death protein-1 antibodies is not common. This condition may be life threating. Diagnosis remain clinical and laboratory. Treatment requires pituitary hormones replacement.
Keywords: Checkpoint inhibitors, Programmed cell death protein-1 inhibitor, Hypophysitis.
References
- S. Department Of Health And Human Services NioH, National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE) 2009; (updated june 14, 2010)
- Baxi S, Yang A, Gennarelli RL, Khan N, Wang N, Boyce L, Korenstein D: Immune-related adverse events for anti-PD-1 and PD-L1 drugs: systematic review and meta-analysis. BMJ 2018;360:k793 http://dxdoi.org/10.1136bmj.k793
- González-Rodriguez E, González-Rodriguez D: Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 2016;21:7:804-816
- Angelousi A, Chatzellis E, Kaltsas G: New molecular, biological, and Immunological agents inducing hypophysitis. Neuroendocrinology 2018;106:89-100
- Lin CH, Chen KH, Chen KY, Shih SR, Lu JY: Immune checkpoint inhibitor therapy-induced hypophysitis – a case series of Taiwanese patients. J Formos Med Assoc 2019; 118:1 Pt 3:524-